Global HR+/HER2- Breast Cancer Market 2016: Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market?

Dublin, Aug. 11, 2016 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Breast Cancer: HR+/HER2-" report to their offering.

Ibrance's continued uptake and the approvals of several pipeline therapies will drive the growth of the HR+/HER2- breast cancer market.

This report addresses the following questions:

- Which branded therapies will have the largest impact on the HR+/HER2- breast cancer market?
- What is the overall market potential for first-in-class product Ibrance?
- How will competing CDK4/6 inhibitors ribociclib and abemaciclib fare following the earlier launch of Ibrance?
- How will PI3K inhibitors alpelisib, buparlisib, and taselisib be positioned in the market?
- When will generic and biosimilar therapies enter the market and what impact will they have on revenues?

Key Topics Covered:

FORECAST: HR+/HER2 BREAST CANCER

- Abemaciclib
- Afinitor (everolimus)
- Alpelisib
- Avastin (bevacizumab)
- Buparlisib
- Entinostat
- Faslodex (fulvestrant)
- Halaven (eribulin mesylate)
- Ibrance (palbociclib)
- Ixempra (ixabepilone)
- Lynparza (olaparib)
- Niraparib
- Ribociclib
- Talazoparib
- Taselisib
- Veliparib
- Primary Research Methodology

TREATMENT: HR+/HER2 BREAST CANCER

- Primary Research Methodology
- Disease Definition and Diagnosis
- Patient Segmentation
- Country Treatment Trees
- Current Treatment Options
- Prescribing Trends
- Unmet Needs in HR+/HER
- Breast Cancer

EPIDEMIOLOGY: HER+/HER2 BREAST CANCER

- Disease Background
- Sources and Methodology
- Forecast
- Epidemiologist Insight
- Strengths and Limitations

MARKETED DRUGS: HR+/HER2 BREAST CANCER

- Product profile: Afinitor
- Product profile: Avastin
- Product profile: Faslodex
- Product profile: Halaven
- Product profile: Ibrance
- Product profile: Ixempra

PIPELINE: HR+/HER2 BREAST CANCER

- Product profile (late stage): Lynparza
- Product profile (late stage): abemaciclib
- Product profile (late stage): alpelisib
- Product profile (late stage): buparlisib
- Product profile (late stage): entinostat
- Product profile (late stage): niraparib
- Product profile (late stage): ribociclib
- Product profile (late stage): talazoparib
- Product profile (late stage): taselisib
- Product profile (late stage): veliparib

For more information visit http://www.researchandmarkets.com/research/2slmd4/breast_cancer

                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                    
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    
                             U.S. Fax: 646-607-1907
                             Fax (outside U.S.): +353-1-481-1716